Total Return chart Formycon AG

Equities

Market Closed - Xetra Other stock markets 16:35:32 23/01/2026 GMT			After hours 17:48:29
23.70 ^EUR	-1.25%		23.60	-0.42%

12-23	Formycon Obtains US FDA Approval for Interchangeable Lucentis Biosimilar	MT
12-23	Formycon AG - FDA approves biologics license application (BLA) for additional ranibizumab biosimilar under trade name Nufymco	RE

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.